Yahoo Web Search

Search results

    • Small Business - Salisbury Post | Salisbury Post

      The Salisbury Post· 10 hours ago

      New data from the ELATIVE® Phase III trial show 70% of patients treated with elafibranor achieved composite endpoint of slowing disease progression measured by biochemical response after 78-weeksData from the itch domain of the PBC-40 and 5-D

    • Donald Trump's abortion problem

      Newsweek· 3 days ago

      Former president Donald Trump has been dodging difficult questions about abortion as he seeks a second term, working to navigate an issue widely seen as an election liability for Republicans ...

    • Pet Talk: Managing Neonatal Maladjustment Syndrome

      The Marshall News Messenger· 2 days ago

      Although rare, neonatal maladjustment syndrome (NMS) can be a challenging and potentially serious condition for foals as they struggle to adapt to life outside the womb due to neurological abnormalities ...